Septerna (SEPN) Projected to Post Earnings on Thursday

Key Points

• Septerna (NASDAQ: SEPN) is set to release its Q2 2025 earnings on August 21st, with analysts expecting a loss of ($0.05) per share.
• The company reported a significant miss in its last earnings, posting ($0.56) earnings per share and revenues of only $0.12 million, well below the $22.50 million estimate.
• Despite recent performance challenges, Septerna's stock has risen 4.4% and analysts maintain a consensus rating of "Moderate Buy" with an average target price of $26.75.

Septerna (NASDAQ:SEPN - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 21st. Analysts expect Septerna to post earnings of ($0.05) per share for the quarter.

Septerna (NASDAQ:SEPN - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.51). The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $22.50 million. Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. On average, analysts expect Septerna to post $-7 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Septerna Stock Up 4.4%

Septerna stock opened at $11.69 on Thursday. The stock has a market capitalization of $520.88 million and a PE ratio of -1.16. Septerna has a twelve month low of $4.17 and a twelve month high of $28.99. The company has a 50 day moving average of $11.47 and a 200-day moving average of $9.27.

Wall Street Analyst Weigh In

SEPN has been the topic of a number of recent research reports. HC Wainwright initiated coverage on shares of Septerna in a report on Monday, June 23rd. They issued a "buy" rating and a $26.00 price objective on the stock. Wells Fargo & Company lifted their price objective on shares of Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a report on Friday, May 16th. Finally, Cantor Fitzgerald lifted their price objective on shares of Septerna from $20.00 to $25.00 and gave the company an "overweight" rating in a report on Friday, May 16th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Septerna has a consensus rating of "Moderate Buy" and an average target price of $26.75.

Institutional Trading of Septerna

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Woodline Partners LP increased its holdings in shares of Septerna by 94.2% during the 1st quarter. Woodline Partners LP now owns 582,585 shares of the company's stock worth $3,373,000 after acquiring an additional 282,585 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Septerna by 19.1% during the 2nd quarter. Geode Capital Management LLC now owns 487,956 shares of the company's stock worth $5,158,000 after acquiring an additional 78,316 shares during the last quarter. CW Advisors LLC acquired a new position in shares of Septerna during the 2nd quarter worth approximately $133,000. Rhumbline Advisers increased its holdings in shares of Septerna by 22.5% during the 2nd quarter. Rhumbline Advisers now owns 28,572 shares of the company's stock worth $302,000 after acquiring an additional 5,254 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Septerna by 15.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company's stock worth $107,000 after acquiring an additional 1,315 shares during the last quarter.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.